Innoviva INVA
NASDAQ INVA
$21.33 -0.02 (-0.09%)
As of: Sep 4, 2026 · 3:59 PM EDT

Innoviva (INVA) Long-Term Investments (2012 - 2026)

Innoviva's (INVA) quarterly Long-Term Investments came in at $413.1 million in Q1 2026, up 41.9% YoY from $291.1 million in Q1 2025, and up 2.12% on a QoQ basis from $404.5 million in Q4 2025.

Analysis

Innoviva (INVA) Long-Term Investments (2012 - 2026) Analysis & Trends

Innoviva (INVA) has 11 years of Long-Term Investments data on file, last reported at $413.1 million in Q1 2026.

  • Quarterly Long-Term Investments rose 41.9% year-over-year to $413.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $413.1 million (up 41.9% YoY) and the FY2025 annual result came in at $404.5 million, up 18.39% from the prior year.
  • Long-Term Investments climbed to $413.1 million in Q1 2026, from $404.5 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $544.4 million in Q1 2022 to a low of $291.1 million in Q1 2025.
  • A 5-year average of $412.0 million and a median of $413.1 million in 2026 frame the typical range for Long-Term Investments.
  • Annual changes were most pronounced in 2025 — Long-Term Investments slumped 38.91% — and 2026, when it soared 41.9%.
  • Tracing INVA's Long-Term Investments over 5 years: stood at $363.9 million in 2022, then grew by 22.14% to $444.4 million in 2023, then decreased by 23.12% to $341.7 million in 2024, then climbed by 18.39% to $404.5 million in 2025, then climbed by 2.12% to $413.1 million in 2026.
  • The last three Long-Term Investments figures came in at $413.1 million (Q1 2026), $404.5 million (Q4 2025), and $343.8 million (Q3 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Investments (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 5.79 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 9.83 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -4.00 Mn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 1.77 Bn
5 Revolution Medicines 44.33 Bn 44.33 Bn - -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn -
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 22.17 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn - 372.10 Mn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn -
10 Innoviva 1.56 Bn 984.81 Mn 90.62 Mn 441.31 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 441.31 Mn
Mar 31, 2026 413.08 Mn
Dec 31, 2025 404.50 Mn
Sep 30, 2025 343.79 Mn
Jun 30, 2025 297.28 Mn
Mar 31, 2025 291.10 Mn
Dec 31, 2024 341.66 Mn
Sep 30, 2024 434.17 Mn
Jun 30, 2024 444.66 Mn
Mar 31, 2024 476.55 Mn
Dec 31, 2023 444.43 Mn
Sep 30, 2023 422.49 Mn
Jun 30, 2023 397.94 Mn
Mar 31, 2023 400.89 Mn
Dec 31, 2022 363.86 Mn
Sep 30, 2022 489.11 Mn
Jun 30, 2022 494.10 Mn
Mar 31, 2022 544.44 Mn
Dec 31, 2021 483.85 Mn
Sep 30, 2021 507.12 Mn